When Bausch Health’s plaque psoriasis combo drug Duobrii was rejected by the FDA in June, analysts read it as a major setback for the company’s reboot plan. But after a meeting with the FDA, that hurdle could now be cleared
read moreMore turnover is coming to Allergan’s board—and this time, it’s the man who arguably built the company. Paul Bisaro, one-time CEO and chairman, and its leader through multiple iterations, is retiring from a director post he’s held since 2007. More:
read moreJohnson & Johnson’s Invokana, Merck’s Steglatro and AstraZeneca’s Farxiga are among the 13 diabetes drugs to carry new warnings about a risk for Fournier’s gangrene, a rare but potentially serious condition linked to SGLT2 inhibitors, the FDA said. More: FDA
read moreAstraZeneca says the European Commission has approved a new formulation of its once-weekly diabetes drug Bydureon. More: EU approves AZ’ Bydureon BCise device Source: News
read moreUK analytics group Genomics plc has signed a three-year deal with Vertex centred on improving the discovery of targets for precision medicine, and has also raised £25 million to further expand its business. More: Vertex invests in Genomics plc as
read moreEuropean regulators have expanded the scope of Amgen’s Blincyto to include the treatment of younger patients with a rare type of leukaemia. More: EU expands use of Amgen’s Blincyto Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals